Role of HBsAg Testing in the Management of Patients with Chronic HBV

被引：4
作者：
Hong T.-C. [1 ]
Yang H.-C. [1 ,2 ]
Kao J.-H. [1 ,2 ,3 ]
机构：
[1] Department of Internal Medicine, National Taiwan University Hospital, Taipei
[2] Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, 1 Chang-Te Street, Taipei
[3] Hepatitis Research Center, National Taiwan University Hospital, Taipei
来源：
Current Hepatology Reports | 2019年 / 18卷 / 3期
关键词：
Antiviral therapy; Chronic hepatitis B; Functional cure; HBsAg quantification; Hepatitis B virus;
D O I：
10.1007/s11901-019-00484-y
中图分类号：
学科分类号：
摘要：
Purpose of Review: HBsAg has been an important serological marker for the diagnosis of hepatitis B virus (HBV) infection. Recently, HBsAg quantification has been utilized to predict the disease activity and the response to antiviral treatment. This review aims to update the clinical utility of HBsAg quantification in the management of chronic hepatitis B (CHB). Recent Findings: HBsAg level varies across different phases of the natural history of CHB, highest in the immune-tolerant phase and lowest in inactive carriers. HBsAg level is useful to stratify the risk of hepatocellular carcinoma in low-viremic patients. HBsAg level also helps predict the HBsAg loss in HBeAg-negative patients. Moreover, baseline level and on-treatment kinetics of HBsAg are associated with the treatment response to pegylated interferon and nucleos(t)ide analogs in both HBeAg-positive and HBeAg-negative patients. Finally, HBsAg level can serve as a therapeutic endpoint marker for evaluating novel curative agents against HBV infection. Summary: HBsAg quantification can help guide the management of CHB. © Springer Science+Business Media, LLC, part of Springer Nature 2019.
引用
收藏
页码：331 / 341
页数：10
相关论文
共 89 条
[21]  
Chan H.L., Wong V.W., Wong G.L., Tse C.H., Chan H.Y., Sung J.J., A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B, Hepatology, 52, 4, pp. 1232-1241, (2010)
[22]  
Jaroszewicz J., Calle Serrano B., Wursthorn K., Deterding K., Schlue J., Raupach R., Et al., Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective, J Hepatol, 52, 4, pp. 514-522, (2010)
[23]  
Nguyen T., Thompson A.J., Bowden S., Croagh C., Bell S., Desmond P.V., Et al., Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia, J Hepatol, 52, 4, pp. 508-513, (2010)
[24]  
New Insights into HBV Replication: New Opportunities for Improved Therapies
[25]  
Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., Romagnoli V., Cherubini B., Moscato G., Maina A.M., Cavallone D., Bonino F., Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers, Gastroenterology, 139, 2, pp. 483-490, (2010)
[26]  
Brouwer W.P., Chan H.L., Brunetto M.R., Martinot-Peignoux M., Arends P., Cornberg M., Et al., Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up, Clin Gastroenterol Hepatol, 14, 10, pp. 1481-1489, (2016)
[27]  
Liu J., Yang H.I., Lee M.H., Jen C.L., Batrla-Utermann R., Lu S.N., Wang L.Y., You S.L., Chen C.J., Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression, Hepatology, 64, 2, pp. 381-389, (2016)
[28]  
Lin L.Y., Wong V.W., Zhou H.J., Chan H.Y., Gui H.L., Guo S.M., Et al., Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients, J Med Virol, 82, 9, pp. 1494-1500, (2010)
[29]  
Tseng T.C., Liu C.J., Yang W.T., Chen C.L., Yang H.C., Su T.H., Wang C.C., Kuo S.F.T., Liu C.H., Chen P.J., Chen D.S., Kao J.H., Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters, J Gastroenterol Hepatol, 29, 6, pp. 1242-1249, (2014)
[30]  
Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., Iloeje U.H., Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 1, pp. 65-73, (2006)
123456789